EMA
safety_alert
· 2019-03-20
Increased risk of blood clots in lungs and death with higher dose of Xeljanz (tofacitinib) for rheumatoid arthritis
Summary
EMA warns that higher doses of tofacitinib (Xeljanz) for rheumatoid arthritis are associated with an increased risk of blood clots in the lungs and death; patie…
Upgrade for the full analysis, importance score, and drug timeline.